In the present study, we showed the prognostic predictive ability of PBRM1 loss in nonmetastatic ccRCC, while Cai et al. also showed that PBRM1 could improve the predictive accuracy for survival outcomes of metastatic RCC patients treated with tyrosine kinase inhibitors (TKIs) [34]. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.